Skip to main content
Figure 5 | Journal of Experimental & Clinical Cancer Research

Figure 5

From: Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Figure 5

IC 50 values for the targeted drugs bortezomib, sorafenib, sunitinib and rapamycin in all tumor samples investigated divided for the subtypes indicated. Results are presented as mean values + SE. Number of samples investigated for each drug and type of sample is indicated on the x-axis labeling. Statistical interference was calculated with one-way ANOVA with Dunnet’s post-test and with the colorectal cancer samples as reference. *P < 0.05; NS, not statistically significant.

Back to article page